Aeterna Zentaris Gmbh

Zentaris Gmbh

Merck Patent Gmbh

Æterna Zentaris Gmbh

Eckhard Claus

Irene Seipelt

Emmanuel Polymeropoulos

Eckhard Guenther

Tilmann Schuster

Matthias Gerlach

Eckhard Günther

Ulf R Rapp

Michael Czech

Ludmilla Wixler

Andreas Bathe

Wolfgang Hierse

Steffen Schellenberger

Jan Krause

Melanie Kleineidam

The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to processes for the preparation of these compounds.

Fluorosurfactants

Pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans. A compound according to the general formula (I) 

Pyridopyrazine derivatives and their use

A method of modulating one or more of ras-Raf-Mek-Erk signal transduction pathway, PI3K-Akt signal transduction pathway and SAPK signal transduction pathway with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2,3-b]pyrazine-6-yl]thiourea, its geometric isomer, or its tautomer.

Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea

Method of modulating ras-Raf-Mek-Erk signal transduction pathway, PI3K-Akt signal transduction pathway and/or SAPK signal transduction pathway with a pyrido[2,3-b]pyrazine of formula (Ia).

Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines

1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-b]pyrazine-6-yl]thiourea which HAS activity to the modulation of misdirected cellular signal transduction processes such as tyrosine kinases, serine/threonine kinases and/or lipid kinases.

Pyridopyrazine derivatives, process of manufacturing and uses thereof

The invention provides quinoxalines of the general formula I which are used as medicaments preferably for treating tumour disorders, in particular in cases of drug resistance to other active compounds and in cases of metastasic carcinoma. The possible applications are not limited to tumour disorders. 

Quinoxaline derivatives and their use for treating benign and malignant tumour disorders

The invention relates to pyrido[2,3-b]pyrazines of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations. 

Pyridopyrazines and their use as modulators of kinases

The invention relates to pyrido[2,3-b]pyrazine compounds of formulae (Ia) and (Ib) which have activity to the modulation of misdirected cellular signal transduction processes such as tyrosine kinases, serine/threonine kinases and/or lipid kinases, their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations: 

Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations. 

Pyridopyrazines and the use thereof as kinase inhibitors

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations 

Growing community of inventors

Frankfurt-am-Main, Germany

Eckhard Claus